SCHEMBL4022116

SCHEMBL4022116

Cc1cccc([C@@H]2[C@@H](C(=O)c3cccc(F)c3)CN(CCCN3CCN(C)CC3)C[C@H]2C(=O)c2cccc(F)c2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 2/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 4/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.38
BCHE P06276 2/20 0.37
DRD2 P14416 3/20 0.37
DRD4 P21917 1/20 0.37
USP2 O75604 2/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 2/20 0.36
MLNR O43193 1/20 0.36
NR1I2 O75469 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
PGR P06401 1/20 0.36
ADRB1 P08588 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019805 0.91 ALDH1A1 (0.41) CYP2C19CYP2D6ALDH1A1GAAKMT2A
SCHEMBL4780151 0.89 KCNH2 (0.43) ALDH1A1KMT2ADRD2DRD4MEN1
SCHEMBL4772529 0.89 KCNH2 (0.43) ALDH1A1KMT2ADRD2DRD4MEN1
SCHEMBL4021786 0.87 ALDH1A1 (0.42) ALDH1A1GAAKMT2AHPGDMEN1
SCHEMBL4026452 0.87 ALDH1A1 (0.40) CYP2C9CYP2C19CYP2D6ALDH1A1GAA
SCHEMBL4028159 0.86 ALDH1A1 (0.39) CYP2C9CYP2C19CYP2D6ALDH1A1GAA
SCHEMBL4020789 0.86 NPC1 (0.43) ALDH1A1KMT2AUSP2ADRA1AKCNH2
SCHEMBL4020787 0.86 NPC1 (0.43) ALDH1A1KMT2AUSP2ADRA1AKCNH2
SCHEMBL4024121 0.86 NPC1 (0.43) ALDH1A1KMT2AUSP2ADRA1AKCNH2
SCHEMBL4021692 0.84 ALDH1A1 (0.38) CYP2C9CYP2C19ALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 CYP2C9 3168/4885CYP2C19 2371/4885CYP2D6 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.